Herpes simplex virus oncolytic therapy for pediatric malignancies
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Apr 2009 · 1 min read
In brief
In brief
This review examines oncolytic herpes simplex virus therapy as an emerging treatment for chemotherapy-resistant pediatric cancers including brain tumors, neuroblastomas, and sarcomas. The article discusses therapeutic potential and translational challenges that must be overcome before clinical implementation in children.
Written by the GCMD Library team from the article.
Statements in this article
A subset of pediatric cancer patients have disease resistant to traditional therapies such as surgery, chemotherapy, and radiation.
Patients with treatment-resistant pediatric cancers require newer, targeted treatments used alone or in combination with more traditional approaches.
Oncolytic herpes simplex virus (HSV) offers promise for several difficult to treat pediatric malignancies.
Oncolytic HSV therapy has potential benefit in pediatric solid tumors including brain tumors, neuroblastomas, and sarcomas.
Many challenges need to be addressed prior to moving oncolytic HSV therapy from the laboratory to the bedside in the pediatric population.